|
1
|
Daneyemez M, Gezen F, Canakci Z and
Kahraman S: Radical surgery and reoperation in supratentorial
malignant glial tumors. Minim Invasive Neurosurg. 41:209–213. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stephenson KB, Barra NG, Davies E, Ashkar
AA and Lichty BD: Expressing human interleukin-15 from oncolytic
vesicular stomatitis virus improves survival in a murine metastatic
colon adenocarcinoma model through the enhancement of anti-tumor
immunity. Cancer Gene Ther. 19:238–246. 2012. View Article : Google Scholar
|
|
3
|
McBride WH: Integration of adenovirus
thymidine kinase suicide-gene therapy with surgery and radiation
therapy for malignant glioma. Future Oncol. 8:17–20. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Srivastava D, Joshi G, Somasundaram K and
Mulherkar R: Mode of cell death associated with adenovirus-mediated
suicide gene therapy in HNSCC tumor model. Anticancer Res.
31:3851–3857. 2011.PubMed/NCBI
|
|
5
|
Munger W, DeJoy SQ, Jeyaseelan R Sr, et
al: Studies evaluating the antitumor activity and toxicity of
interleukin-15, a new T cell growth factor: comparison with
interleukin-2. Cell Immunol. 165:289–293. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Carson WE, Giri JG, Lindemann MJ, et al:
Interleukin (IL) 15 is a novel cytokine that activates human
natural killer cells via components of the IL-2 receptor. J Exp
Med. 180:1395–1403. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mrozek E, Anderson P and Caligiuri MA:
Role of interleukin-15 in the development of human CD56+
natural killer cells from CD34+ hematopoietic progenitor
cells. Blood. 87:2632–2640. 1996.PubMed/NCBI
|
|
8
|
Sparano JA, Fisher RI, Weiss GR, et al:
Phase II trials of high-dose interleukin-2 and lymphokine-activated
killer cells in advanced breast carcinoma and carcinoma of the
lung, ovary, and pancreas and other tumors. J Immunother Emphasis
Tumor Immunol. 16:216–223. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chapoval AI, Fuller JA, Kremlev SG, Kamdar
SJ and Evans R: Combination chemotherapy and IL15 administration
induce permanent tumor regression in a mouse lung tumor model: NK
and T cell-mediated effects antagonized by B cells. J Immunol.
161:6977–6984. 1998.PubMed/NCBI
|
|
10
|
Lasek W, Basak G, Switaj T, et al:
Complete tumour regressions induced by vaccination with IL-12
gene-transduced tumour cells in combination with IL15 in a melanoma
model in mice. Cancer Immunol Immunother. 53:363–372. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rubinstein MP, Kadima AN, Salem ML, Nguyen
CL, Gillanders WE and Cole DJ: Systemic administration of IL15
augments the antigen-specific primary CD8+ T cell
response following vaccination with peptide-pulsed dendritic cells.
J Immunol. 169:4928–4935. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Croce M, Meazza R, Orengo AM, et al:
Sequential immunogene therapy with interleukin-12- and
interleukin-15-engineered neuroblastoma cells cures metastatic
disease in syngeneic mice. Clin Cancer Res. 11:735–742.
2005.PubMed/NCBI
|
|
13
|
Suzuki K, Nakazato H, Matsui H, et al: NK
cell-mediated anti-tumor immune response to human prostate cancer
cell, PC-3: immunogene therapy using a highly secretable form of
interleukin-15 gene transfer. J Leukoc Biol. 69:531–537.
2001.PubMed/NCBI
|
|
14
|
Kimura K, Nishimura H, Hirose K,
Matsuguchi T, Nimura Y and Yoshikai Y: Immunogene therapy of murine
fibrosarcoma using IL15 gene with high translation efficiency. Eur
J Immunol. 29:1532–1542. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ponnazhagan S, Curiel DT, Shaw DR, Alvarez
RD and Siegal GP: Adeno-associated virus for cancer gene therapy.
Cancer Res. 61:6313–6321. 2001.PubMed/NCBI
|
|
16
|
Xiao X, Li J and Samulski RJ: Efficient
long-term gene transfer into muscle tissue of immunocompetent mice
by adeno-associated virus vector. J Virol. 70:8098–8108.
1996.PubMed/NCBI
|
|
17
|
Jennings K, Miyamae T, Traister R, et al:
Proteasome inhibition enhances AAV-mediated transgene expression in
human synoviocytes in vitro and in vivo. Mol Ther. 11:600–607.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jooss K, Yang Y, Fisher KJ and Wilson JM:
Transduction of dendritic cells by DNA viral vectors directs the
immune response to transgene products in muscle fibers. J Virol.
72:4212–4223. 1998.PubMed/NCBI
|
|
19
|
Emborg ME, Carbon M, Holden JE, et al:
Subthalamic glutamic acid decarboxylase gene therapy: changes in
motor function and cortical metabolism. J Cereb Blood Flow Metab.
27:501–509. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kaplitt MG, Feigin A, Tang C, et al:
Safety and tolerability of gene therapy with an adeno-associated
virus (AAV) borne GAD gene for Parkinson’s disease: an open label,
phase I trial. Lancet. 369:2097–2105. 2007.PubMed/NCBI
|
|
21
|
Yu YL, Wei CW, Chen YL, Chen MH and Yiang
GT: Immunotherapy of breast cancer by single delivery with
rAAV2-mediated interleukin-15 expression. Int J Oncol. 36:365–370.
2010.PubMed/NCBI
|
|
22
|
Yiang GT, Chou PL, Tsai HF, et al:
Immunotherapy for SV40 T/t antigen-induced breast cancer by
recombinant adeno-associated virus serotype 2 carrying
interleukin-15 in mice. Int J Mol Med. 29:809–814. 2012.PubMed/NCBI
|
|
23
|
Yiang GT, Harn HJ, Yu YL, et al:
Immunotherapy: rAAV2 expressing interleukin-15 inhibits HeLa cell
tumor growth in mice. J Biomed Sci. 16:472009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kayama T, Kumabe T, Tominaga T and
Yoshimoto T: Prognostic value of complete response after the
initial treatment for malignant astrocytoma. Neurol Res.
18:321–324. 1996.PubMed/NCBI
|
|
25
|
Kowalczuk A, Macdonald RL, Amidei C, et
al: Quantitative imaging study of extent of surgical resection and
prognosis of malignant astrocytomas. Neurosurgery. 41:1028–1038.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li YM and Hall WA: Targeted toxins in
brain tumor therapy. Toxins (Basel). 2:2645–2662. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ahmed AU, Ulasov IV, Mercer RW and Lesniak
MS: Maintaining and loading neural stem cells for delivery of
oncolytic adenovirus to brain tumors. Methods Mol Biol. 797:97–109.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim CY, Park SH, Jeong M, et al:
Preclinical studies for pharmacokinetics and biodistribution of
Ad-stTRAIL, an adenovirus delivering secretable trimeric TRAIL for
gene therapy. Exp Mol Med. 43:580–586. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee EX, Lam DH, Wu C, et al: Glioma gene
therapy using induced pluripotent stem cell derived neural stem
cells. Mol Pharm. 8:1515–1524. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
King GD, Muhammad AK, Larocque D, et al:
Combined Flt3L/TK gene therapy induces immunological surveillance
which mediates an immune response against a surrogate brain tumor
neoantigen. Mol Ther. 19:1793–1801. 2011. View Article : Google Scholar
|
|
31
|
Heilbronn R and Weger S: Viral vectors for
gene transfer: current status of gene therapeutics. Handb Exp
Pharmacol. 143–170. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lundstrom K: Gene therapy applications of
viral vectors. Technol Cancer Res Treat. 3:467–477. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang L, Calcedo R, Nichols TC, et al:
Sustained correction of disease in naive and AAV2-pretreated
hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy.
Blood. 105:3079–3086. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Flannery JG, Zolotukhin S, Vaquero MI,
LaVail MM, Muzyczka N and Hauswirth WW: Efficient
photoreceptor-targeted gene expression in vivo by recombinant
adeno-associated virus. Proc Natl Acad Sci USA. 94:6916–6921. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Snyder RO and Flotte TR: Production of
clinical-grade recombinant adeno-associated virus vectors. Curr
Opin Biotechnol. 13:418–423. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li SF, Wang RZ, Meng QH, et al:
Intra-ventricular infusion of rAAV1-EGFP resulted in transduction
in multiple regions of adult rat brain: a comparative study with
rAAV2 and rAAV5 vectors. Brain Res. 1122:1–9. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dong JY, Fan PD and Frizzell RA:
Quantitative analysis of the packaging capacity of recombinant
adeno-associated virus. Hum Gene Ther. 7:2101–2112. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chiu TL, Lin SZ, Hsieh WH and Peng CW:
AAV2-mediated interleukin-12 in the treatment of malignant brain
tumors through activation of NK cells. Int J Oncol. 35:1361–1367.
2009.PubMed/NCBI
|
